18F-氟昔洛韦PET在放疗后生化复发前列腺癌中的双中心回顾分析
本研究回顾性纳入两家三级机构100例初始放疗后PSA升高的前列腺癌患者,评估18F-氟昔洛韦PET的检出率与诊断准确性。患者水平总检出率为79%(79/100),PSA低于Phoenix标准者阳性率为62%(23/37),阳性预测值为89%(95%CI:80-94%)。PSA速度对PET结果预测价值最高,PSADT和PSA速度与盆腔外转移相关。
要点
- 18F-氟昔洛韦PET在放疗后生化复发患者中总检出率为79%。
- PSA低于Phoenix标准者仍有62%PET阳性,低PSADT或高PSA速度者更易检出。
- 低PSADT或高PSA速度与盆腔外转移概率增加相关。
核心结论
- 18F-氟昔洛韦PET可在低PSA水平及PSA升高未达Phoenix标准的放疗后疑似生化复发患者中识别复发灶。
- 低PSADT或高PSA速度患者盆腔外转移概率增加,更可能从PET/CT或PET/MRI而非单纯盆腔MRI中获益。
研究设计与样本
- 双中心回顾性研究,纳入100例初始外照射放疗、近距离放疗和/或质子治疗后PSA升高的前列腺癌患者。
- 采用逻辑回归和ROC曲线分析评估18F-氟昔洛韦PET的诊断准确性及PSA动力学参数与PET结果的关系。
主要发现
- 患者水平总检出率为79%(79/100)。
- PSA低于Phoenix标准者18F-氟昔洛韦PET阳性率为62%(23/37)。
- 18F-氟昔洛韦PET阳性预测值为89%(95%CI:80-94%)。
- PSA低于Phoenix标准者中,PSA速度对PET结果的预测价值最高。
- PSADT和PSA速度与盆腔外转移性疾病的存在相关。
临床怎么用
- 对放疗后生化复发且PSA低于Phoenix标准的患者,可考虑18F-氟昔洛韦PET以识别复发灶。
- PSADT低或PSA速度高的患者盆腔外转移概率增加,宜优先选择PET/CT或PET/MRI而非单纯盆腔MRI。
局限性
- 回顾性研究设计。
- 仅纳入两家三级机构患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 18F-Fluciclovine PET imaging has been increasingly used in the restaging of prostate cancer patients with biochemical recurrence (BCR); however, its clinical utility in patients with low prostate-specific antigen (PSA) levels following primary radiation therapy has not been well-studied. This study aims to determine the detection rate and diagnostic accuracy of 18F-fluciclovine PET and the patterns of prostate cancer recurrence in patients with rising PSA after initial radiation therapy, particularly in patients with PSA levels below the accepted Phoenix definition of BCR (PSA nadir +2 ng/mL). METHODS: This retrospective study included patients from two tertiary institutions who underwent 18F-fluciclovine PET scans for elevated PSA level following initial external beam radiation therapy, brachytherapy, and/or proton therapy. Logistic regression and receiver operating characteristic (ROC) curve analyses were performed to determine the diagnostic accuracy of 18F-fluciclovine PET and associations of PSA kinetic parameters with 18F-fluciclovine PET outcome. RESULTS: One hundred patients were included in this study. The overall detection rate on a patient-level was 79% (79/100). 18F-Fluciclovine PET was positive in 62% (23/37) of cases with PSA below the Phoenix criteria. The positive predictive value of 18F-fluciclovine PET was 89% (95% CI: 80-94%). In patients with PSA below the Phoenix criteria, the PSA velocity had the highest predictive value of 18F-fluciclovine PET outcome. PSA doubling time (PSADT) and PSA velocity were associated with the presence of extra-pelvic metastatic disease. CONCLUSION: 18F-Fluciclovine PET can identify recurrent disease at low PSA level and PSA rise below accepted Phoenix criteria in patients with suspected BCR after primary radiation therapy, particularly in patients with low PSADT or high PSA velocity. In patients with low PSADT or high PSA velocity, there is an increased probability of extra-pelvic metastases. Therefore, these patients are more likely to benefit from PET/CT or PET/MRI than pelvic MRI alone.
引用
- Salavati A, Gencturk M, Koksel Y, et al. A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria? Eur J Nucl Med Mol Imaging. 2021. PMID: 34091713. doi:10.1007/s00259-021-05415-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。